Highest-materiality recent filing
Cardinal Health Q3 revenue +11% to $60.9B, non-GAAP EPS $3.17 (+35%), raises FY26 outlook
Non-GAAP EPS $3.17, up 35% YoY; GAAP EPS $1.69, down 20% on $184M goodwill impairment in Navista & ION.
Revenue $65.6B (+19% YoY); GAAP diluted EPS $1.97 (+19%); non-GAAP diluted EPS $2.63 (+36%).
Cardinal Health raises FY2026 non-GAAP EPS outlook to at least $10.00, up from $9.65-$9.85
Raises FY2026 non-GAAP diluted EPS guidance to at least $10.00 from prior range of $9.65-$9.85.
Cardinal Health Q1 revenue $64B (+22%), non-GAAP EPS $2.55 (+36%); raises FY2026 guidance
Revenue $64B (+22% YoY); GAAP diluted EPS $1.88 (+11%); non-GAAP diluted EPS $2.55 (+36%).
Cardinal Health issues $1B in notes to partially fund Solaris Health acquisition
Issued $600M of 4.500% notes due 2030 and $400M of 5.150% notes due 2035.
Q4 revenue $60.2B flat YoY (+21% excluding contract expiration); non-GAAP EPS $2.08 (up 13%).
Cardinal Health raises FY25 EPS guidance to $8.15-$8.20; sets FY26 preliminary EPS $9.10-$9.30
Raising FY25 non-GAAP diluted EPS to $8.15-$8.20 (from $8.05-$8.15); 9% growth at midpoint.
Cardinal Health Q3 non-GAAP EPS $2.35, up 13% YoY; raises FY25 EPS guidance to $8.05-$8.15
Revenue $54.9B flat YoY; up 19% ex-customer contract expiration.
Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal
Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.
Cardinal Health raises FY2025 non-GAAP EPS guidance to high end of $7.75-$7.90 range
Now expects FY2025 non-GAAP EPS toward high end of $7.75 to $7.90, driven by Pharmaceutical & Specialty Solutions strength.
Cardinal Health enters $1.0B term loan for acquisitions of GI Alliance and Advanced Diabetes
$1.0B aggregate term loan facility to pay cash consideration and transaction costs for pending acquisitions of GI Alliance (majority equity) and Advanced Diabetes Supply Group.
Issued $500M of 4.700% Notes due 2026, $750M of 5.000% Notes due 2029, $1B of 5.350% Notes due 2034, and $650M of 5.750% Notes due 2054.
Cardinal Health acquires 71% of GI Alliance for ~$2.8B and ADSG for ~$1.1B
Acquires 71% stake in GI Alliance (gastroenterology MSO) for ~$2.8B cash; remaining ~29% callable at fair value after 3 years.
Cardinal Health Q1 GAAP EPS $1.70; Non-GAAP EPS $1.88, up 9% YoY; Raises FY25 guidance
Revenue $52.3B, down 4% (up 15% ex-large customer expiration); Pharmaceutical segment profit up 16% to $530M.
Q4 revenue $59.9B (+12% YoY); GAAP EPS $0.96, non-GAAP EPS $1.84 (+29%).
Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40
Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
Max materiality 0.90 · Median 0.68 · Most common event earnings